Home > Boards > US OTC > Cannabis >

Cannabis Science, Inc. (CBIS)

Add CBIS Price Alert      Hide Sticky   Hide Intro
Moderator: Fuzzy Bunny, Taurus69, Homebrew, $Pistol Pete$
Search This Board: 
Last Post: 5/17/2019 10:32:18 AM - Followers: 1287 - Board type: Free - Posts Today: 0



Contact Us
Cannabis Science, Inc.
6946 North Academy Boulevard
Suite B #254
Colorado Springs, CO 80918
Email: info@cannabisscience.com
Tel: +1 (888) 777-0658
Fax: +1 (866) 943-5085

Robert Kane - CFO & Director
Email: robert.kane@cannabisscience.com
Tel: +1 (561) 420-4824


                                         The Science of Cannabinoids

Recent advances in science have opened the door to develop, produce, and commercialize, a variety of effective whole plant cannabinoid based pharmaceutical products with a wide variety of important applications.
Although cannabis has been used medicinally for thousands of years, until very recently little was known about how it actually worked. Some uses of cannabis are well known, such as alleviating nausea and stimulating the appetite for people with AIDS and cancer.

Other well-known uses include chronic pain, and reducing muscle spasms associated with neuromuscular disorders like MS and spinal cord injuries. Some current uses are poorly understood, such as its effectiveness in alleviating certain autoimmune disorders such a Crohn's Disease.


Our Market

The mainstream pharmaceutical industry is capital-intensive and constrained by high regulatory hurdles, making the profitability of any particular product a long-term prospect. Cannabis Science™ is different in three key respects:
The Company will, at least in its first phase of existence, deal primarily in intellectual properties "patents on products and processes" leaving capital-intensive problems such as regulatory compliance, mass production and marketing to the "old guard" pharmaceutical companies who license our patents.
We will focus on a relatively new and under-explored niche in the pharmaceutical market: Whole-plant cannabinoid compounds derived from certified organic ingredients. The existing pharmaceutical industry is heavily geared, by inclination and in terms of infrastructure, toward the development and testing of synthetic compounds.
Cannabis Science™ has strong roots in, and an established relationship of trust with, the US and Canadian medical cannabis patient communities. In the course of product and process development, we'll do "well" by doing "good" - our products will receive baseline efficacy testing in that community. Since medical cannabis already inherently exceeds all reasonable standards of safety, potential licensees will approach the regulatory process with a reasonable expectation that the products and processes they license will easily exceed that process's safety and efficacy standards. Thus our products and processes will enjoy a significant advantage over previously untested synthetics.


Executive Management click

Board Of Directors

Dr. Robert J. Melamede, Ph.D.  - President & Director
Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Advisory Board of The Journal of the International Association for Cannabis as Medicine, and the Scientific Advisory Board Medical of the Marijuana Policy Advocacy Project, as well as the Scientific Advisory Board of Americans for Safe Access. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.

Dr. Dorothy Bray, Ph.D. - Chief Executive Officer and Director
Dr. Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline. Dr. Bray held various positions of responsibility at GlaxoSmithKline.

Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
Robert Kane - Chief Financial Officer and Director
Mr. Kane wrote his first business plan in 1996. In 1998, he was hired at Ryan, Beck, and Company, which was bought by the 120-year-old, top ten, financial firm Stifel Nicolaus (NYSE: SF) as a registered representative.  
On December 31,
2009, Mr. Kane walked away from the financial markets and started his own firm, Robert Kane Partners, which specializes in business and management planning, investor presentations, and investor relations.  
Mr. Kane held the position of Director of Investor Relations for Medical Marijuana, Inc., the first ever publicly traded medical marijuana company. He also held the position of Chief Financial Officer for “Cannabiz Business University.”  Robert Kane's mission is transforming and leading the Medical Cannabis Industry into a viable investment alternative for all types of investors.


Scientific Advisory Board click

Dr. Roscoe M. Moore, Jr., D.V.M., Ph.D., D.Sc.
Until his retirement, Dr. Roscoe M. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for global development support within the Office of the Secretary, HHS, with primary emphasis on Continental Africa and other less developed countries of the world. He was the principal liaison person between the HHS and Ministries of Health in Africa with regard to the development of infrastructure and technical support for the delivery of preventive and curative health needs for the continent.Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop.
Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (CDC). He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.

Dr. Dorothy Bray, Ph.D.
Dr. Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline, to the Company’s Scientific Advisory Board. Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
Dr. Bray’s extensive experience in the field of HIV drug development will compliment Cannabis Sciences’ prestigious Scientific Advisory Board as the company embarks on the research and development of a phytocannabinoid based HIV TAT inhibitor. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs.


Policy Advisory Board

Robert Raich Esq
Robert A. Raich practices law in Oakland, California, and is a graduate of Harvard University and the University of Texas School of Law. He is one of the most respected attorneys in the area of medical marijuana. He is General Counsel of the Oakland Cannabis Buyers' Cooperative, and was one of the attorneys in the U.S. Supreme Court case, United States v. Oakland Cannabis Buyers' Coop. and another federal medical cannabis case. He is a member of the California Attorney General's Medical Marijuana Task Force (Chairman, Caregiver Issues Subcommittee).

Sean T. McAllister Esq
Sean T. McAllister is public interest attorney with offices in Denver and Summit County. Sean has been involved with drug policy reform efforts for over a decade. Sean serves as the Chair of the Board of Directors of Sensible Colorado. Sean is a lifetime member of the NORML Legal Committee. He is a member and Board member of the Colorado Criminal Defense Bar. He helped start the Colorado Bar Association Criminal Sentencing Project in 2005 to focus on criminal justice and drug policy reform. Recently, Sean was appointed to the Governor's Drug Policy Task Force, which is working on reducing drug-sentencing laws to save the state money while maintaining public safety. Along with Brian Vicente, Sean recently founded the Canna-Business Institute designed to educate dispensary owners and caregivers on how to legally operate medical marijuana businesses in Colorado.

Warren Edson Esq
Warren Edson is an experienced criminal defense lawyer in Colorado having taken part in over 1,000 trials. He is also one of the organizers of Colorado's Medical Marijuana Law, Amendment 20, and is a Lifetime Member, NORML Legal Committee, and is a member, Colorado Criminal Defense Bar, and the National Association of Criminal Defense Lawyers, and is a Board Member, Colorado NORML.

Robert J. Corry, Jr. Esq
Robert J. Corry, Jr. is a Denver-based civil rights and criminal defense attorney, specializing in medical marijuana, who has successfully litigated several high profile cases around the country. He is admitted to the bars of Colorado, California, and Washington, D.C., federal courts in these jurisdictions, as well as the U.S. Supreme Court. Mr. Corry earned his law degree from Stanford University.

Brian Vicente, Esq
Brian Vicente, Esq., a Denver defense attorney who serves as executive director of Sensible Colorado, the states leading non-profit working for medical marijuana patients and caregivers. He is also the chairman of the Denver Mayor's Marijuana Policy Review Panel and coordinates the Colorado Bar Association's Drug Policy Project. He was awarded the prestigious Gideon award for his free speech advocacy during the 2008 Democratic National Convention.


Products Overview

Our products, broadly described, is medical cannabis - a term which encompasses a wide variety of products, ranging from plants grown by patients for their own use to pharmaceutical products developed from one or more of the cannabinoid compounds found in the whole cannabis plant.

Cannabinoids are a group of terpenophenolic compounds present in Cannabis (Cannabis sativa L). Currently, 538 natural compounds were identified from this plant.  43 of these 108 are identified as cannabinoids, which are C21 compounds uniquely present in Cannabis sativa L. There are ten main types of cannabinoids and fourteen different cannabinoid subtypes. Tetrahydrocannabinol (THC) is the principal psychoactive ingredient in cannabis, but it also has other effects. Cannabidiol (CBD) and cannabinol (CBN) are the other two most prevalent natural cannabinoids and have received the most study. All three are listed as ingredients in Sativex®, the only multi-cannabinoid medicine currently approved for marketing (only in Canada.)

Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. THC was not identified until 1964, but by that time cannabis had been removed from the pharmacopeiae of most countries, making further research on the plant difficult.

There are three general types of cannabinoids:
1) Phytocannabinoids that occur uniquely in the cannabis plant.
2) Endogenous cannabinoids produced naturally in many animal species including humans.
3) Synthetic cannabinoids are similar compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, synthetic THC is marketed as Marinol®.
Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.
Cannabinoid receptors in the human body were not discovered until 1990. CB1 receptors are found primarily in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.
CB1 receptors appear to be responsible for the euphoric and anti-convulsive effects of cannabis.


Investors Overview

Cannabis Science Inc.
Trading Symbol: CBIS

Transfer Agent 
Securities Transfer Corporation 
2591 Dallas Parkway 
Suite 102 
Frisco, Texas 75034 
Telephone: (469) 633-0101 ext. 201 
Fax: (469) 633-0088 
Website: www.stctransfer.com

Common Class B
  Common Class A

Common, Class B
29,744,774 a/o Dec 32, 2009
101,170,574 a/o Dec 31, 2010
305,820,574 a/o Dec 31, 2011
602,170,573 a/o May 21, 2012 
691,770,573 a/o Aug 13, 2012
699,290,000 a/o Nov 8, 2012
714,540,573 a/o Nov 19, 2012
704,290,573 a/o Dec 17, 2012
823,523,000 a/o Mar 13, 2014

2,327,855,296 a/o Sep 30, 2016

Common, Class A

Stock Chart

Proposed Dividend / Share Structure

UPDATE NEWS 08-18-2015


EXCERPT /////\\\\\

CBIS to Start Issue of Dividend Payments
Cannabis Science to Issue Dividend Payouts
for Previous and Current Shareholders,
a $15-25 Million Capital Raise for FDA and
Other Clinical Drug Development Programs as Well as a Proposed NASDAQ Up Listing

9:36 am ET August 18, 2015 (Market Wire) Print
Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines,

is pleased to announce the closure and issuance of the previously filed dividend share payout as filed with the S.E.C. on a Definitive Schedule 14C on August 18, 2011,

the Definitive Schedule 14C filing (RULE 14c-101).

The Company also intends to file another Information Statement to accommodate new shareholders to date to receive a similar dividend payout,

to bring all shareholders in on what the Company considers a landmark growth curve.

The Company expects to accelerate its current FDA targeted drug development programs and expand its State-by-State initiatives.

Increasing shareholder value is of foremost importance for everyone involved;

to this end the Company will apply for a unique trading symbol to accommodate a $15 - 25 million USD range financing it has been actively negotiating for the newly created class of dividend payout Common A stock,

and formally pursue a contemplated up listing to NASDAQ.

The Company expects to begin filing the complete new structure program with no reverse split by the end of the month.

Cannabis Science, Inc. (the "Company") wishes to update its current and former shareholders regarding the previously approved share dividend, which was filed on a Definitive Schedule 14C with the Commission on August 18, 2011.

The Company will use its best efforts to issue the share dividend, which is one new share of Class A common stock for each ten shares of common stock that they owned as of December 31, 2010.

In addition to this dividend, the Company intends to file a new Information Statement pursuant to Section 14(C) to issue a new dividend to shareholders as of October 9, 2015.

Both dividends will also carry a warrant that will give each shareholder of record a share purchase warrant consisting of an option to purchase one additional share of Class A common stock for each special dividend share received.

Each warrant will be exercisable into one share of Class A stock at a price of $1.00 per share for a period of three months after all the proposed changes officially take effect.

The Company also plans to apply for a unique and separate trading symbol for its shares of Class A common stock.


New Share Structure
On December 20, 2010, our Board of Directors approved an amendment to the Articles of Incorporation to effect a recapitalization of the Company by establishing two classes of common stock, Class A and Class B and to issue a dividend to holders of our current common stock so they received 1 share of the new Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the former Class B common stock that they previously owned as of the current record date, December 31, 2010. Each whole share purchase warrant will be exercisable into one share of Class A common stock at a price of $1.00 per share. The share purchase warrants expire 90-days from the date Class A common stock commences trading under its own unique symbol. The Company is working diligently with the SEC and FINRA to obtain final approvals before any of the proposed changes can take effect.

DEF 14C Filed to give Dividend and Create New Share Class


* Dividend will go to shareholders as of Dec 31, 2010
* Shareholders will receive 1 share of Class A stock (the new ticker) for every 10 shares of the current stock
* Shareholders will receive 1 purchase warrant for every 10 shares of the current stock. The warrants can be used to purchase Class A stock at $1 for 90 days.

Dividends (April 23, 2013)-10-K
The Company declared a dividend to all common stockholders of record as of December 31, 2010, whom are to receive a dividend equivalent to ten percent (10%) of the number of common shares of the Company's stock held on that date in the form of newly issued Series A common shares. For example, if a stockholder held 100,000 common shares on December 31, 2010, that stockholder would receive a dividend of 10,000 Series A common shares. This dividend is on hold and will remain pending until such time as FINRA approves the Company's Series A common stock for trading, it obtains a CUSIP registration number, it receives sponsorship from a brokerage firm, and the shares become tradable through the OTCBB market. TheCompany retains the right to adjust the shareholder record date should any factor make it impossible for the Company to issue the dividend to shareholders of record on December 31, 2010, including, but not limited to: approval of the Series A common stock and dividend by FINRA, a detailed December 31, 2010 common stockholder lists is available, or other unforeseen obstacles that would prevent the current dividend structure from completing. The Company will not make any share accrual or allowance for this dividend until such time as all regulatory approvals are in place for the Series A common stock to be issued and become a marketable security.
The Company does not anticipate paying cash dividends or making distributions in the foreseeable future.
We currently intend to retain and reinvest future earnings, if any, to finance and expand our operations.
We incurred a net loss of $86,574,241 since January 27, 2005 (date of inception) to December 31, 2012.
Our net loss increased, from $8,339,044 for the fiscal year ended December 31, 2011 to $16,037,572 at the fiscal year ended
December 31, 2012, an increase of $7,698,528. For the fiscal year ended December 31, 2012, our net loss per share was $0.03,
compared to a net loss per share of $0.05 per share for the fiscal year ended December 31, 2011.
The Company is authorized to issue 850,000,000 shares of common stock with a par value of $.001 per share. These shares
have full voting rights. There were 663,790,573 issued and outstanding as of December 31, 2012.
The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $.001 per share.
These shares have 10 votes per share. There were 0 issued and outstanding as of December 31, 2012.
The Company is also authorized to issue 1,000,000 shares of preferred stock. These shares have full voting rights of 1,000
votes per share. On December 20, 2012 the former CFO of the Company, Richard Cowan, resigned and notified the Company
of his forfeiture of 333,333 series A preferred shares for return into treasury of the Company. There were 666,666 issued and
outstanding series A preferred shares as of December 31, 2012 as a result of this forfeiture.

On February 9, 2012, the Company established a 2012 Equity Compensation Plan that authorizes the Company to issue up to
50,000,000 common shares to staff or consultants for services to or on behalf of the Company. The Company filed a
Registration Statement Form S-8 with the U.S. Securities
Our management conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria
set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated
Framework at December 31, 2012. Based on its evaluation, our management concluded that, as of December 31, 2012, our
internal control over financial reporting was not effective because of limited staff and a need for a full-time chief financial
officer. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial
statements will not be prevented or detected on a timely basis.





2014 Financial Highlights (from 10-K)

Net Loss $ 16,884,764  (2013:5,934,301)

Accumulated Deficit  $ 109,393,306 (2013: 92,508,542)

Revenue (educational and consulting)  $ 1,031



Repeated Pump & Dump.
No Products, or Promised Dividend.
Buyer Beware

More Scam related DD: http://cannabissciencecontroversy.blogspot.com/2018/02/cannabis-science-inc-purchase-of-pre.html

2015 (9 months) Highlights: 
Revenue $4,150,
Net Loss $14,204,900  !!


Sept 2016

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern.  The Company reported an accumulated deficit of $139,971,991and had a stockholders’ deficit of $4,344,643 as of September 30, 2016.


Is this CBIS International Headquarters, Research Center??


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CBIS News: Amended Annual Report (10-k/a) 04/15/2019 05:32:03 PM
CBIS News: GDET UP 300% To $0.01 On 300M Traded In 2 Weeks; Positioning For Run To $0.06 04/03/2019 03:22:34 PM
CBIS News: GDET CBD Product Reveal Tomorrow Could Trigger $0.01 Run to $0.06 04/01/2019 01:07:27 PM
CBIS News: Marijuana Stocks Big Announcement Coming Soon for 2019 03/31/2019 03:49:14 PM
CBIS News: Marijuana Stocks Big Announcement Coming Soon for 2019 03/31/2019 03:49:14 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#126456  Sticky Note $CBIS Cannabis Science Negotiates for Major Asset Backed $Pistol Pete$ 12/26/17 08:35:49 PM
#126330  Sticky Note Simple scorecard: Fuzzy Bunny 12/04/17 06:42:41 PM
#112944  Sticky Note Beware the CBIS SCAM!! Good DD here exposing Homebrew 05/01/15 09:10:13 PM
#128717   International Phytomedicines Institute for global health and development Buildi U ROCK 05/17/19 10:32:18 AM
#128716   Sorry, CBIS's 100% scam. Dabney can talk all Homebrew 05/16/19 09:06:45 PM
#128715   https://www.globalhealthcatalystsummit.org/phytomedicines-in-global-health Mharris35 05/16/19 08:08:10 PM
#128714   Yes I agree Mharris35 05/16/19 08:07:37 PM
#128713   It's a scam. Keep reading these various dschultz26 05/16/19 03:00:31 PM
#128711   Dabney is speaking at the Global Health Catalyst Joanna A 05/16/19 12:31:32 PM
#128708   He bought a bunch of black ties and dschultz26 05/15/19 02:16:59 PM
#128707   Mr Dabney...what happened to CBIS shareholder capital? freemoneyfella 05/15/19 01:17:49 PM
#128705   https://walletinvestor.com/stock-forecast/cbis-stock-prediction Mharris35 05/13/19 07:20:28 PM
#128704   https://walletinvestor.com/stock-forecast/cbis-stock-prediction Mharris35 05/13/19 07:19:33 PM
#128703   Mr. Kaalo C. Dabney is not considered a Fuzzy Bunny 05/13/19 04:03:00 PM
#128702   CBIS .01 with SCAM news dschultz26 05/12/19 08:27:03 AM
#128701   $cbis $.10 with news Taurus69 05/10/19 06:32:34 PM
#128700   https://docs.wixstatic.com/ugd/7c636d_ebf64531c4434f898c8b0711a9e87225.pdf Lo Mharris35 05/10/19 11:38:43 AM
#128699   https://www.google.com/amp/s/insiderfinancial.com/cannabis-science-inc-otcmktscb Mharris35 05/10/19 11:18:20 AM
#128697   Are we nearing a historical entry point? MikeyInTheD 05/07/19 04:58:44 PM
#128696   What product? There is no company to mte1955 05/07/19 01:39:45 PM
#128695   Anyone using CBIS products sicofbs 05/02/19 04:04:13 PM
#128694   $CBIS 10 days 30' chart $Pistol Pete$ 04/30/19 08:44:48 PM
#128693   CBIS .01 with SCAM news dschultz26 04/29/19 08:21:52 AM
#128692   $cbis $.10 with news Taurus69 04/27/19 05:27:14 AM
#128691   At .0333 your gift was a dollar 9 U ROCK 04/26/19 12:56:10 PM
#128690   Lol... ten years he’s been defrauding investors and sicofbs 04/23/19 04:36:01 PM
#128689   I have been holding this dog for a fleitz 04/22/19 04:19:47 PM
#128688   Mr. Dabney has been stealing shareholder capital for freemoneyfella 04/17/19 02:55:13 PM
#128687   From updated filing. What a scam. dschultz26 04/16/19 08:39:19 AM
#128686   Did they just file an amendment on their MrTrader129 04/15/19 07:55:16 PM
#128685   I say it all of the time. dschultz26 04/15/19 12:46:06 PM
#128684   If memory serves that is the same thing.... LongShot_Louie 04/15/19 12:00:12 PM
#128683   As with most of these announcements, we will dschultz26 04/15/19 11:26:39 AM
#128682   I'll say it again, Dorothy did her job.... LongShot_Louie 04/15/19 10:21:30 AM
#128681   Independent Valuation of U.S. Patent Number 9,763,991 for joaopaulo 04/15/19 08:10:17 AM
#128680   Any reason why it will make a move dschultz26 04/11/19 08:06:45 AM
#128679   CBIS looking like it will make a move LouWho 04/10/19 07:38:16 PM
#128678   Convinced most of the volume in CBIS are freemoneyfella 04/10/19 02:43:22 PM
#128677   His other pot failure ENDO had a 100k sicofbs 04/10/19 02:29:27 PM
#128676   CBIS is a fake news company. Ray freemoneyfella 04/10/19 10:32:46 AM
#128675   As usual, more news about something that they dschultz26 04/10/19 10:16:17 AM
#128674   8:52 AM ET 4/10/19 / GlobeNewswire Dean14 04/10/19 09:14:56 AM
#128672   $cbis $.10 with news Taurus69 04/09/19 05:09:42 AM
#128671   CBIS's Scam-a-Riffic!! Scam-Tastic...Amazed it's still trading. Homebrew 04/08/19 10:04:31 PM
#128670   Thanks inorout. I think i'll be ok. WinniG 04/05/19 08:09:45 AM
#128669   CBIS is a bagholder stock and perfect for you. freemoneyfella 04/05/19 12:46:24 AM
#128668   Can you provide any links? Please stop WinniG 04/03/19 06:49:30 PM
#128666   How’s that CBIS Black Tie Gala? Awesome freemoneyfella 04/03/19 03:54:48 PM
#128665   Agreed $Pistol Pete$ 04/02/19 11:28:32 PM
#128664   Calirx was served by S.E.C today with CHOsin 04/02/19 08:49:48 PM
#128663   I don't disagree with anything you've said. jjr04001 04/02/19 02:19:36 PM
#128662   Problem is charts are a rear view look freemoneyfella 04/02/19 02:13:28 PM
#128661   Charts don't tell you why. They just jjr04001 04/02/19 10:34:37 AM